Nektar Therapeutics (NKTR) Tops Q4 EPS by 19c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $65.70 --0%
Revenue Growth %: -7.1%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: -7.1%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of $0.03, $0.19 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $29.2 million versus the consensus estimate of $29.81 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- IceCure cites journal article on cryoablation vs. RFA for breast cancer
- Contango Silver & Gold starts drilling at Lucky Shot, updates on key projects
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
